Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In its first major refresh since its establishment in 2018, the BioEscalator is delighted to welcome five leading University of Oxford academics and innovators to its Management Board. The Management Board provides a source of expertise for BioEscalator tenants and works to enhance research at the University by building strong links with small life sciences companies.

Five board members

Peter Callow is a seasoned finance executive with extensive international experience in financial management, strategic planning, and leadership.

Professor Catherine Green OBE is Head of the Clinical Biomanufacturing Facility at Nuffield Department of Medicine and Associate Professor in Chromosome Dynamics at the Centre for Human Genetics. She played a key role in developing the Oxford/AstraZeneca Covid-19 vaccine.

Professor Bethan Psaila is an Associate Professor of Haematology and Cancer Research at MRC Weatherall Institute of Molecular Medicine; she is also Co-founder of a blood malignancies company and BioEscalator tenant Alethiomics.

Professor Molly Stevens DBE is John Black Professor of Bionanoscience at the Institute of Biomedical Engineering and the Department of Physiology, Anatomy & Genetics and research director for biomedical materials at Imperial College London.

Professor Krina Zondervan is Head of the Nuffield Department of Women's & Reproductive Health, Professor of Reproductive and Genomic Epidemiology, and Co-Director of the Endometriosis Care Centre.

 

Read the full story on the BioEScalator website. 

Similar stories

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Researchers from the Nuffield Department of Primary Care Health Sciences contribute to parliamentary calls for overhaul of obesity care

Research from the Health Behaviors team has informed a series of parliamentary reports calling for urgent action to tackle obesity in England.

Oxford University invites 100,000 people to take part in a major study of plant-based diets

Researchers at the Nuffield Department of Population Health have launched a major new study designed to generate the most up-to-date picture of different diets in the UK, including plant-based diets, and how they affect long-term health and wellbeing.

Look beyond my skin: your psoriasis could help us understand who develops psoriatic arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

Professor Matthew Wood receives BioUK Special Recognition Award 2026

Professor Matthew Wood, Director and Chief Scientific Officer of the Oxford-Harrington Rare Disease Centre (OHC), has received BioUK’s Special Recognition Award 2026 for his contribution to rare disease research, therapeutic development and the wider life sciences sector.

University of Oxford and BIIE launch collaboration in translational immune engineering

Researchers from the Department of Paediatrics at the University of Oxford and the Botnar Institute of Immune Engineering (BIIE) came together in Oxford last week for the inaugural scientific meeting of the new Basel–Oxford Centre for Translational Immune Engineering for Child and Adolescent Health (CTIE).